Seres Therapeutics Announces Receipt Of $125M Milestone From Nestlé Health Science Following FDA Approval Of VOWST
Portfolio Pulse from Benzinga Newsdesk
Seres Therapeutics has received a $125M milestone payment from Nestlé Health Science following the FDA approval of VOWST. This payment is part of their ongoing collaboration to develop microbiome-based therapies.
May 30, 2023 | 8:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Seres Therapeutics' receipt of $125M from Nestlé Health Science following FDA approval of VOWST strengthens their financial position and supports ongoing collaboration.
The $125M milestone payment from Nestlé Health Science to Seres Therapeutics (MCRB) following the FDA approval of VOWST is a significant financial boost for the company. This payment supports their ongoing collaboration to develop microbiome-based therapies, which could lead to more revenue-generating opportunities in the future. As a result, this news is likely to have a positive short-term impact on MCRB's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100